SCM
ACTU

Sterling Capital Management’s Actuate Therapeutics ACTU Stock Holding History

Sterling Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40
Closed -$110 – 3438
2026
Q1 		$110 Hold
40
– – ﹤0.01% 3199
2025
Q4 		$245 Buy
40
+25
+167% +$172 ﹤0.01% 3218
2025
Q3 		$100 Buy
15
+1
+7% +$7 ﹤0.01% 3234
2025
Q2 		$86 Buy
+14
New +$122 ﹤0.01% 3252

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Sterling Capital Management's ACTU Position: Q2 2026 in Review

Sterling Capital Management sold out of Actuate Therapeutics (ACTU) in Q2 2026, closing a stake of 40 shares — an estimated $110 sold.

Sterling Capital Management first reported a position in ACTU in Q2 2025 and held it in 4 quarters. The position peaked at $245 in Q4 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Sterling Capital Management reported no remaining Actuate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sterling Capital Management sold 40 Actuate Therapeutics shares in Q2 2026, an estimated $110.
  • Sterling Capital Management first reported a position in Actuate Therapeutics in Q2 2025 and held it in 4 quarters.
  • Sterling Capital Management's Actuate Therapeutics position peaked at $245 in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.